Our Studies/ Scientific Programs

CURRENTLY ENROLLING The MIMIC clinical trial is open for enrollment. Ethos Discovery is investigating a new minimally-invasive surgical treatment for canine osteosarcoma that has metastasized, or spread, to the lungs. This study is subsidized and all procedures will be provided at an affordable, low cost. Eligibility Criteria: • Dogs weighing >5 kgs with a diagnosis

CURRENTLY ENROLLING Participate in our study, clear up your dog’s recurrent episodes of diarrhea, and we’ll cover the vet bills! This study will evaluate a new and rigorously developed probiotic to treat dogs suffering from regular bouts of diarrhea. All dogs participating in the study will receive medical care. Eligibility Criteria: • Adult dogs over

Ethos Precision Medicine Umbrella Study for Hemangiosarcoma (ePUSH) CURRENTLY ENROLLING Hemangiosarcoma (HAS) is a highly aggressive cancer affecting dogs, often leading to sudden and severe health crises. This study aims to find new treatments for hemangiosarcoma, offering hope for improved outcomes and reducing unnecessary euthanasia for splenic tumors. ELIGIBILITY CRITERIA: • Any dog diagnosed with

We are collecting blood samples from eligible French Bulldogs to research biomarkers associated with hemorrhages (bleeding) in French bulldogs.

Ethos Discovery seeks to investigate a new approach to reducing hemorrhages (bleeding) in French Bulldogs following slipped discs in their back.

Current chemotherapy treatments involve a direct injection into the tumor. We would like to use surgically removed lung tissue to better understand how drugs behave when they are injected into lung tumors in dogs, as well as humans, with lung tumors.

Postoperative regurgitation is a common side effect of general anesthesia; it is of clinical concern due to the increased risk of pneumonia. This study seeks to define the rate at which intravenously administered MNTX in healthy dogs is metabolized. Once defined, a future study will evaluate the efficacy of this treatment in reducing postoperative regurgitation in dogs.

Necrotizing Meningoencephalitis in Pugs (PDE) is a devastating disease. Clinical signs include seizures, circling, cognitive changes, and visual deficits. Our goal is to identify neurological abnormalities in Pugs with high genomic risk for PDE before the onset of the above-mentioned advanced clinical signs.

We are studying a novel live probiotic product typically found in the gut of healthy dogs to evaluate the ability of this probiotic to resolve diarrhea in dogs.

Proliferating cell nuclear antigen (PCNA) is an important protein necessary for the repair of DNA in cells. Cancer cells express a unique type of PCNA (termed caPCNA) which is only found at small quantities in non-cancer cells.

Verdinexor is a chemotherapy drug that has been conditionally approved by the FDA for the treatment of canine lymphoma. Verdinexor is a selective inhibitor of nuclear export (SINE) compound, and this family of drug has demonstrated encouraging results in preclinical studies when combined with other chemotherapeutic drugs.

Pneumonia (infection in the lungs) is a common diagnosis in dogs and cats and can be caused by a variety of pathogens (i.e., bacteria, viruses, fungal organisms). Collecting fluid samples from the lungs of patients with pneumonia allows for tests to be performed that can identify the organism causing the infection.